Invivo Anti-Human IL-6 Recombinant mAb

Interleukin-6 (IL-6) is a four-helix bundle type I pleiotropic cytokine encoded by the IL6 gene (located on chromosome 7p21), with a mature molecule of 184 amino acids and a molecular weight of approximately 21–28 kDa. It is rapidly produced by monocytes and macrophages upon infection or tissue injury, and eliminates pathogens and repairs tissue by activating immune, hematopoietic, and acute-phase responses. IL-6 signal transduction features a unique two-pathway design: classical signaling recruits gp130 homodimers through membrane-bound IL-6Rα (expressed only on hepatocytes, certain leukocytes, and epithelial cells) and mainly mediates anti-inflammatory and regenerative functions; trans-signaling, in which a complex formed by soluble IL-6Rα (sIL-6R) and IL-6 activates almost all cells expressing gp130, is considered the principal pathway underlying the pro-inflammatory pathological effects of IL-6. Dimerization of gp130 activates downstream cascades such as JAK/STAT3 and MAPK, and IL-6-induced STAT3 activation can further upregulate IL6 transcription, forming an inflammatory amplification loop. Under physiological conditions, IL-6 participates in hematopoietic regulation, acute-phase protein synthesis (such as CRP, SAA, and fibrinogen), and metabolic regulation; however, when persistently overexpressed, it becomes a key driver of rheumatoid arthritis, Castleman disease, cytokine storms, and various cancers.